<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02373163</url>
  </required_header>
  <id_info>
    <org_study_id>INTERVENCION Trial</org_study_id>
    <nct_id>NCT02373163</nct_id>
  </id_info>
  <brief_title>INTERVENCION Trial</brief_title>
  <acronym>INTERVENCION</acronym>
  <official_title>Characterization of Arterial Hypertension and Efficacy of Blood-pressure Lowering Therapy at Different Altitudes Above Sea Level</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prevencion</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prevencion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is designed to:

        1. Assess the response to montherapy with : a thiazide diuretic (HCTZ), a calcium-channel
           blocker (CCB, amlodipine) and an angiotensin-receptor blocker (telmisartan), among
           hypertensive subjects who live at sea level, at medium altitude above sea level and at
           high altitude above sea level.

        2. To test whether diferentes exist in the response to therapy among subjects who live at
           different altitude above sea level

        3. To assess the hemodynamic characteristics of hypertension in populations that live at
           sea level, at medium altitude above sea level, and at high altitude above sea level.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change is 24-hour Systolic blood pressure from baseline to 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with controlled BP at 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hour Diastolic blood pressure from baseline to 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hour Mean arterial pressure from baseline to 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24 hour Pulse pressure from baseline to 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Central (aortic) pulse pressure from baseline to 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Carotid-femoral pulse wave velocity from baseline to 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the magnitude of Wave reflections from baseline to 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Blood Pressure, High</condition>
  <arm_group>
    <arm_group_label>Diuretic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Therapy with hydrochlorothiazide (25 mg daily) taken once daily between 6 and 8 AM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium-channel blocker</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angiotensin Receptor Blocker</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Arm: Active Comparator: Diuretic Therapy with hydrochlorothiazide (25 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Calcium-channel blocker Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Angiotensin Receptor Blocker Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM</description>
    <arm_group_label>Diuretic</arm_group_label>
    <other_name>HCTZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM</description>
    <arm_group_label>Calcium-channel blocker</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <description>Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM</description>
    <arm_group_label>Angiotensin Receptor Blocker</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 45-75 years. Enrollment will be stratified by age group (50-65 and 66-80 years),
             gender and altitude above sea level

          2. Leaving in the enrollment cities for at least 2 years

          3. Untreated hypertension for at least 2 weeks

          4. Systolic BP between 140 and 160 mmHg and/or diastolic BP between 90 and 99 mmHg, in
             the absence of therapy.

        Exclusion Criteria:

          1. Diabetes mellitus.

          2. Chronic kidney disease (estimated glomerular filtration rate &lt;60 ml / minute / 1.73 m2
             of body surface area.

          3. Smoking.

          4. Lung disease, liver disease or active cancer

          5. Any factor that, in the opinion of the investigator, decreases short-term survival

          6. Psychiatric illness

          7. Inability to provide informed consent

          8. Established heart disease (previous myocardial infarction, heart failure, valvular
             heart disease, cardiomyopathy, atrial fibrillation or any significant cardiac
             arrhythmia)

          9. History of cerebrovascular disease

         10. History of orthostatic hypotension.

         11. History of syncope.

         12. History of allergy of adverse effects to study medications or drugs of the same
             pharmacologic classes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Josefina E Medina-Lezama, MD</last_name>
    <phone>+5154251269</phone>
    <email>Josefina Medina &lt;jmedinal2911@gmail.com&gt;</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro de Investigacion PREVENCION</name>
      <address>
        <city>Arequipa</city>
        <state>AQP</state>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josefina E Medina-Lezama, MD</last_name>
      <phone>+5154251269</phone>
      <email>Josefina Medina &lt;jmedinal2911@gmail.com&gt;</email>
    </contact>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <reference>
    <citation>Medina-Lezama J, Zea-Diaz H, Morey-Vargas OL, Bolaños-Salazar JF, Postigo-Macdowall M, Paredes-Díaz S, Corrales-Medina F, Valdivia-Ascuña Z, Cuba-Bustinza C, Villalobos-Tapia P, Muñoz-Atahualpa E, Chirinos-Pacheco J, Raij L, Chirinos JA. Prevalence and patterns of hypertension in Peruvian Andean Hispanics: the PREVENCION study. J Am Soc Hypertens. 2007 May-Jun;1(3):216-25. doi: 10.1016/j.jash.2007.02.003.</citation>
    <PMID>20409853</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>February 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2015</study_first_posted>
  <last_update_submitted>October 19, 2015</last_update_submitted>
  <last_update_submitted_qc>October 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prevencion</investigator_affiliation>
    <investigator_full_name>Josefina Medina-Lezama, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Calcium Channel Blockers</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

